Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17861160 | 0.91 | MEN1 (0.38) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17847829 | 0.90 | ATM (0.40) | KMT2ASLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL17861208 | 0.89 | SLC6A4 (0.38) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17847893 | 0.88 | SLC6A2 (0.46) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17847889 | 0.88 | SLC6A2 (0.46) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17861183 | 0.82 | ALDH1A1 (0.41) | SLC6A2SLC6A4SLC6A3KDM4ETSHR | |
| SCHEMBL17847880 | 0.82 | MEN1 (0.35) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19471251 | 0.82 | SLC6A2 (0.43) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19471158 | 0.81 | MEN1 (0.39) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17861187 | 0.81 | MEN1 (0.35) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | claimed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | claimed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | claimed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| EP-3233805-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | MEN1 4475/4885KMT2A 1196/4885SLC6A2 1232/4885 |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | MEN1 4563/4885KMT2A 1415/4885SLC6A2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.